North America Cervical Cancer Screening Market: By Test Type (Pap Smear Tests, HPV Tests, LBC Tests, and Others), Country (USA, and Canada) and Forecast to 2030

North America Cervical Cancer Screening Market size was valued at US$ 459.3 million in 2023 and is expected to reach US$ 465.8 million by 2030, growing at a significant CAGR of 0.2% from 2024 to 2030. In terms of cervical cancer screening, North America leads the industry by a wide margin. This dominance is fueled by a potent mix of factors that encourage widespread screening and continuous improvement in the healthcare landscape. Total number of tests for cervical cancer done in the USA in 2023 was 11,721,687 and is expected to be 12,589,008 in 2030, amongst which pap smear tests were 72.12%, HPV tests were 23.42% and LBC tests were 4.27%. Further, the total number of tests for cervical cancer in Canada in 2023 was 4,266,355 and is predicted to be 4,672,024 in 2030.

In addition, technological innovation plays a crucial role in driving growth and efficiency in the North American cervical cancer screening market. The introduction of HPV testing, a more sensitive and specific screening tool, has led to earlier detection and improved prevention strategies. Also, the liquid-based cytology (LBC) technique improves the quality of pap smears by preserving more diagnostic cells, leading to increased accuracy and a reduction in false negatives.

Moreover, automation in sample processing and analysis allows for faster turnaround times and increased screening capacity, optimizing workflows and patient experience. Furthermore, the North American healthcare system is constantly evolving to be more patient-centered. The emergence of home-based HPV testing options empowers women who might face barriers to traditional clinical settings by offering increased convenience and privacy. Also, the simultaneous testing for both pap smears and HPV can streamline the screening process and provide more comprehensive results, reducing the need for repeat tests. The integration of telehealth services allows for remote consultations with healthcare providers regarding screening options and results, improving accessibility and convenience. However, ensuring equitable access to screening services for minority communities and women in rural areas remains a crucial concern.

North America Cervical Cancer Screening Market Key Developments:

• In November 2023, Abbott received the US FDA approval for its Alinity high risk (HR) HPV assay. This will add the assay to their molecular diagnostics portfolio. The assay can be used alongside the Pap test.
• In March 2023, The BD Onclarity™ HPV Assay was incorporated into the NHS Cervical cancer screening program, which can be viewed as a big win for the company. The assay allows for at-home collection of vaginal swab samples making it more convenient, easy, accessible, and potentially less uncomfortable for women compared to clinician-taken cervical samples.